Schizophrenia News and Research

Latest Schizophrenia News and Research

Schizophrenia tends to be elevated in more urban communities: Study

Higher rates of schizophrenia in urban areas can be attributed to increased deprivation, increased population density and an increase in inequality within a neighbourhood, new research reveals.

15 Dec 2012

God will control my asthma

Research shows that patients’ belief in God influences how likely they are to be adherent to asthma medication.

14 Dec 2012

Diabetes risk increased in relatives of schizophrenia patients

The prevalence of diabetes is increased in the unaffected relatives of patients with non-affective psychosis, results from a Dutch study show.

14 Dec 2012

Study finds new evidence that vitamin D decreases risk of autism in children

A study just published online in the peer-reviewed journal Dermato-Endocrinology found additional evidence that vitamin D reduces the risk of developing autism.

14 Dec 2012

TUBB5 gene responsible for microcephaly: IMP study

Neurobiologists at the Research institute of Molecular Pathology (IMP) in Vienna have discovered one of the key genes required to make a brain. Mutations in this gene, called TUBB5, cause neurodevelopmental disease in children.

14 Dec 2012

Relatives of schizophrenia patients show cortical thinning

Patients with schizophrenia and their unaffected relatives show significant cortical thinning compared with mentally healthy individuals without such a family history, researchers report.

13 Dec 2012

Fingolimod associated with modest, rapid increase in macular volume

Patients with multiple sclerosis treated with fingolimod undergo a modest but rapid increase in macular volume, research shows.

13 Dec 2012

Many deaths among schizophrenia, bipolar patients ‘avoidable’

More than half of all deaths in patients aged less than 75 years with schizophrenia or bipolar disorder are avoidable, results from a UK study show.

13 Dec 2012

New way to effectively make designer drugs that hit collections of protein targets simultaneously

An international research collaboration led by scientists at the University of North Carolina School of Medicine and the University of Dundee, in the U.K., have developed a way to efficiently and effectively make designer drugs that hit multiple protein targets at once.

13 Dec 2012

Complex process of bone disease evident in mastocytosis

Patients with mastocytosis show elevated bone turnover that is associated with a higher mast cell load and advanced disease relative to individuals without the condition, suggest study findings.

12 Dec 2012

Cognitive retrieval impaired in schizophrenia

Patients with schizophrenia show impairments in the autobiographical memory retrieval brain network, French researchers report.

12 Dec 2012

Many deaths among schizophrenia, bipolar patients ‘avoidable’

More than half of all deaths in patients aged less than 75 years with schizophrenia or bipolar disorder are avoidable, results from a UK study show.

12 Dec 2012

Autism associated with reductions in cellular adhesion molecules in the blood

A new study published in Biological Psychiatry suggests that autism is associated with reductions in the level of cellular adhesion molecules in the blood, where they play a role in immune function.

12 Dec 2012

Lenalidomide effective alternative in lupus

The thalidomide derivative, lenalidomide, is a “safe” and effective treatment in refractory cutaneous lupus erythematosus patients, although three-quarters of patients experience clinical relapse after the drug is withdrawn, say Spanish researchers.

11 Dec 2012

Immune dysfunction pinpointed in developmental disorder

Children with neurodevelopmental abnormalities resulting from duplication of the methyl-CpG binding protein 2 gene also have impaired T-helper-cell 1 responses, research shows.

10 Dec 2012

Novel antidepressant targets brain receptors responsible for learning and memory

A first-of-its-kind antidepressant drug discovered by a Northwestern University professor and now tested on adults who have failed other antidepressant therapies has been shown to alleviate symptoms within hours, have good safety and produce positive effects that last for about seven days from a single dose.

7 Dec 2012

Pesticides in tap water may increase food allergy risk

Having a high level of urinary dichlorophenols is associated with the presence of food sensitization and allergies, say researchers.

7 Dec 2012

CRP40 may have pathogenic role in schizophrenia

Gene expression of catecholamine-regulated protein 40 is dysregulated in people with schizophrenia, study findings show.

7 Dec 2012

Study demonstrates how parasites enter the brain to influence its host

Toxoplasma is a common 'cat parasite', and has previously been in the spotlight owing to its observed effect on risk-taking and other human behaviours. To some extent, it has also been associated with mental illness. A study led by researchers from Karolinska Institutet in Sweden now demonstrates for the first time how the parasite enters the brain to influence its host.

7 Dec 2012

Naurex reports positive results from GLYX-13 Phase IIa trial on depression

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported positive results from a Phase IIa clinical trial of its lead antidepressant compound, GLYX-13.

6 Dec 2012